This study is comparing two FDA-approved laser treatments for glaucoma: Direct Selective Laser Trabeculoplasty (DSLT) and Selective Laser Trabeculoplasty (SLT). Both procedures aim to lower the pressure inside your eye (intraocular pressure or IOP) to help prevent vision loss caused by open-angle glaucoma or ocular hypertension (high eye pressure). DSLT is a newer, non-contact method that might be more comfortable and efficient. You would be randomly assigned to receive either DSLT or SLT. Researchers will follow your eye pressure and safety for 12 months to see how well each treatment works. The study plans to enroll 172 participants. To join, you must be at least 18 years old with open-angle glaucoma or ocular hypertension, and have an open angle in your eye. You cannot participate if you have angle-closure glaucoma, very high eye pressure (over 35 mmHg) despite treatment, or had recent eye surgery.

Study design

This is an interventional study comparing two laser treatments. Participants will be randomly assigned to receive either Direct Selective Laser Trabeculoplasty (DSLT) or Selective Laser Trabeculoplasty (SLT). The study plans to enroll 172 participants.

What's involved

Participants will receive one of two laser treatments and have their eye pressure and safety monitored for 12 months.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 12 months after treatment to assess changes in intraocular pressure.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.